慢性中性粒细胞白血病(chronic neutrophilic leukemia,CNL)是一种骨髓增殖性疾病,其特点为外周血中性粒细胞持续增多,骨髓粒细胞显著增生,脾肿大,pH染色体或BCR-ABL1融合基因阴性.1920年Tuohy[1]首次报道CNL,目前国际报道仅有200多病例.

目的 分析原发性玻璃体视网膜淋巴瘤(primary vit-reoretinal lymphoma,PVRL)的免疫和基因表型,探讨流式细胞和二代测序在PVRL诊断中的作用.方法 回顾性分析3例PVRL的细胞病理学、流式细胞、靶向二代测序或数字PCR等检测结果.结果 3例患者症状不典型,例1和例3从初诊到确诊历经1年左右.3例的流式细胞免疫分型均支持弥漫大B细胞淋巴瘤.例1细胞病理学见异常大淋巴细胞,二代测序发现MYD88 L265P和CD79B Y196H等8个基因突变.例2细胞病理学见异常幼稚大细胞,二代测序发现MYD88 L265P和CD79B Y196N等13个基因突变,房水细胞因子IL-10/IL-6升高.例3数字PCR发现房水MYD88 L265P突变.结论 流式细胞免疫分型是PVRL诊断的实用辅助手段,二代测序有利于探索新的诊断和预后标志物.

目的:探讨中国弥漫性大B细胞淋巴瘤(DLBCL)不同基因分型的患者在基因变异谱系上的特点及其预后差异.方法:收集187例初治非特指型DLBCL患者,行淋巴瘤相关的高通量测序及免疫荧光原位杂交检测,根据基因变异结果进行基因分型,同时收集临床资料进行分析.结果:不同基因分型DLBCL在基因变异谱系上具有较大异质性,其中EZB亚型治疗效果较好,而A53、N1、MCD亚型治疗效果较差.预后方面ST2、EZB亚型患者总体生存期显著优于N1、A53亚型.结论:不同DLBCL基因分型患者的化疗反应、总体生存期具有显著差异.DLBCL基因分型对中国患者的治疗决策及预后评估有重大意义.

Objective To study the effect of the megakaryocyte count method for its classification results.This method can serve as the basis for its normal range.Methods The total number of megakaryocytes of bone marrow aspiration in 262 cases were counted.The number of megakaryocytes per unit area greater than 100 was included into this study.We compared the influence and classificaiton of megakaryocyte at 25,50 and 100 per unit.The megakaryocyte were found according the Bow and W shape.The impact on the classification of megakaryocytes were compared.Results The average number of megakaryocytes in the 262 cases is 48.4 ± 32.2.There was not statistically significant impact on the classification of megakaryocyte in counting of 50 and 100.But there was more promegakaryocytes and less platelet megakaryocyte through W shape.Conclusion Recommended classification 50 megakaryocyte,the megakaryocyte were found according the Bow shape.

Objective: To investigate the expression and clinical significance of the X-linked inhibitor of apoptosis protein(XIAP) in bone marrow biopsy tissue of acute myeloid leukemia and lymphoma.Methods: The expression of XIAP was detected by immunohistochemical assay in the bone marrow biopsy tissue from 10 cases of acute myeloid leukemia,13 lymphoma and 9 patients without hematological malignancy.Results: The level of XIAP in the bone marrow tissue from acute myeloid leukemia and lymphoma was higher than those from control cases without hematological malignancy(P0.05).Conclusion:The increased expression of XIAP protein may contribute to the progression of acute myeloid leukemia and lymphoma,which may be relevant to its role as inhibitor of apoptosis.